Step Pharma reports 83% platelet normalization in high-risk ET trial
AI Summary- Step Pharma will present preliminary VECTRA trial data for dencatistat in high-risk ET.
- 10 of 12 evaluable participants achieved platelet normalization, an 83% response rate.
- The phase 2 trial will enroll up to 50 participants across the US, EU and UK.